Article

PARPis after PARPis in patients with recurrent epithelial ovarian cancer: A single institutional experience

2024-10-11

Abstract excerpt

<title>Abstract</title> <p><bold>Objective</bold> Negligible evidence exists for PARPis maintenance treatment rechallenge in patients with recurrent epithelial ovarian cancer (EOC) in China. <bold>Methods</bold> We included patients diagnosed with primary EOC who received 2 lines of PARPis maintenance treatment after achieving complete response (CR) or partial response (PR) with the previous chemotherapies. The p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ebb82623-f12a-5d8a-989f-b5d2f8900004
DOI: 10.21203/rs.3.rs-4905090/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PARPis after PARPis in patients with recurrent epithelial ovarian cancer: A single institutional experienceDOI 10.21203/rs.3.rs-4905090/v1Read

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.Semantic proximity Read

The effect of PARPi maintenance therapy on re-chemotherapy in advanced ovarian cancerSemantic proximity Read

Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian CancerSemantic proximity Read

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancerSemantic proximity Read

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving StrategiesSemantic proximity Read

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersSemantic proximity Read

Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancerSemantic proximity Read

PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian CancerSemantic proximity Read

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?Semantic proximity Read

PARP inhibitors: Clinical utility and possibilities of overcoming resistanceSemantic proximity Read